IHC staining of the HER2+ breast cancer biopsies indicated that eIF2α-P was more highly increased in tumors after Trastuzumab treatment compared with tumors from the same patients before the treatment (Supplementary Fig. 6). Here, ERBB2 is linked to breast cancer.